Histogenics and FDA Conclude Discussions Regarding NeoCart Phase 3 Clinical Trial Data and Regulatory Pathway
Histogenics and FDA Continue to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart in Patients With Knee Cartilage Damage
CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.